Results 51 to 60 of about 54,096 (328)
Leukemia, 2020 Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival.
M. Talpaz, J. Kiladjian
semanticscholar +1 more source
British Journal of Haematology, 2021 Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400‐mg daily was based on results of an updated analysis of the pivotal phase III ...
A. Pardanani +13 more
semanticscholar +1 more source
Preleukemia: hematological disorders prior to onset of leukemia [PDF]
, 1975 Published data on Japanese leukemia patients with a preleukemic hematological disorder were assessed. The reexamined cases were from the "Japona Centra Revuo Medicina" reported during the period from 1952 to 1971.
Hiraki, Kiyoshi +5 more
core +1 more source
Experimental and Therapeutic Medicine, 2013 The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
Jinjing Tan +8 more
openaire +4 more sources
Disseminated tuberculosis with myelofibrosis presentation: a case report
Journal of Medical Case Reports, 2021 Background Primary myelofibrosis is a rare myeloproliferative disorder in middle-aged and old adults and should be distinguished from secondary and reactive causes of bone marrow fibrosis because, in reactive fibrosis, treatment approaches depend on the ...
Mahdi Khatuni +3 more
doaj +1 more source
Frontiers in Pediatrics, 2021 Secondary hyperparathyroidism (HPT) is a common complication of end-stage renal disease (ESRD) and may be an important precipitating factor for the development of myelofibrosis.
Keishiro Amano +4 more
doaj +1 more source
9q21.13q21.31 deletion in a patient with intellectual disability severe speech delay and and dysmorphic features a newly recognized microdeletion syndrome [PDF]
, 2019 The increased use of chromosomal microarray analysis has led to the identification of new microdeletion/microduplication syndromes, enabling better genotype-phenotype correlations.
Correia, Hildeberto +6 more
core +1 more source
Haematologica, 2016 Myelofibrosis is a myeloproliferative neoplasm that results in cytopenia, bone marrow fibrosis and extramedullary hematopoiesis. Allogeneic hematopoietic stem cell transplantation is the only curative treatment but is associated with a risk of delayed ...
Christina Hart +8 more
doaj +1 more source
Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]
Journal of Clinical and Diagnostic Research, 2018 Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar +4 more
doaj +1 more source
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]
, 2020 Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M +6 more
core